Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 8Recruiting 4Terminated 2Active not recruiting 2

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 87CNS 68Lymphoid 62Gastrointestinal 55Thoracic 50Head & Neck 37Breast 35Other hematologic neoplasm 26Plasma cell 17Gynecologic 16Tumor-Agnostic 15Sarcoma 15Dermatologic 15Endocrine 14NET 9Myeloid 6Other solid neoplasm 4Other neoplasm 3

Conditions

Retinoblastoma 1Malignant Female Reproductive System Neoplasm 1Advanced Solid Tumor 1Advanced Malignant Solid Neoplasm 1

Interventions

Injections 54pembrolizumab 40Carboplatin 20Bevacizumab 19Cyclophosphamide 17toripalimab 14Nivolumab 14Cisplatin 14tislelizumab 13fludarabine 13Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Fluorouracil 10Cetuximab 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Magnetic Resonance Spectroscopy × Other solid neoplasm × Clear all
NCT06126276 2026-06-02

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT05599048 2026-05-27

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05504291 2026-02-17

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Children's Oncology Group

Phase 2 Recruiting
26 enrolled
Other solid neoplasm

Retinoblastoma

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡